Evolocumab (Repatha (R))

被引：0

作者：

Turecek, Claudia ^{[1
]}

机构：

[1] Prinz Eugen Str 8-10, A-1040 Vienna, Austria

来源：

JOURNAL FUR KARDIOLOGIE | 2016年 / 23卷 / 1-2期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：58 / 58

页数：1

共 50 条

[1] Evolocumab (Repatha) for the Treatment of Hyperlipidemia
Erlich, Deborah R.
AMERICAN FAMILY PHYSICIAN, 2016, 94 (10) : 843 - 846
[2] Reduction of Cardiovascular Risk with Evolocumab (Repatha)
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1519): : 63 - 64
[3] Repatha Pushtronex - A New Evolocumab Injection Device
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1503): : 120 - 120
[4] Analysis of the evolocumab (Repatha®) patient support program for patients with cardiovascular disease in Colombia
Garcia-Pena, Angel Alberto
Pineda-Posada, Mariana
Paez-Canro, Carol
Cruz, Cesar
Samaca-Samaca, Daniel
CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2023, 35 (06): : 280 - 289
[5] Evolocumab (Repatha) - A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1479): : 140 - 141
[6] Repatha (R) - Now moved from the Yellow Box!
不详
Journal fur Kardiologie, 2016, 23 (9-10): : 254 - 254
[7] Evolocumab (Repatha)-A Second PCSK9 Inhibitor to Lower LDL-Cholesterol (Reprinted from The Medical Letter on Drugs and Therapeutics, vol 57, pg 140, 2015)
不详
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (21): : 2298 - 2299
[8] Clinical Trial Strategies for Identifying an Evolocumab and Inclisiran Combination Regimen With Improved Safety and Efficacy Over Evolocumab Alone Thomas R Roesel
Roesel, Thomas R.
CIRCULATION, 2017, 136
[9] Evolocumab
不详
AUSTRALIAN PRESCRIBER, 2016, 39 (05) : 180 - 182
[10] Evolocumab in Hyperlipidemia
Meyer, Robert J.
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (09): : 876 - 876

← 1 2 3 4 5 →